Hanimune Therapeutics

Hanimune Therapeutics is a private biotechnology company developing consumer and therapeutic food products for the prevention and management of food allergies. Its core strategy involves the early introduction of precise, reliable quantities of allergenic proteins to build immune tolerance. The company's portfolio includes 'Lil Mixins' for infant diets and 'Top9Proteins' for supporting tolerance at any age, positioning it at the intersection of nutritional science, consumer health, and immunology. Hanimune operates in a high-growth market with significant unmet need, aiming to transform allergy care from reactive avoidance to proactive tolerance building.

A food science and processing platform focused on sourcing and processing common allergenic foods into standardized, reliable formats with consistent protein quantities and allergenicity profiles for tolerance induction.

Hanimune competes in the early allergen introduction space with other CPG brands and infant formula companies. In therapeutic tolerance, it faces competition from FDA-approved drugs (e.g., Aimmune's Palforzia), other biotechs developing OIT therapies, and clinical practices using off-the-shelf foods. Its differentiation lies in its food science expertise and product standardization.